PREFERMS: Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT01623596
Collaborator
(none)
881
123
2
37.1
7.2
0.2

Study Details

Study Description

Brief Summary

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study.

Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

852 Patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved first line DMTs. Patients must be either treatment naive or have received treatment with only one class of treatment (interferon beta preparation or glatiramer acetate) . Patients previously treated with DMT and randomized to the DMT arm may not remain on the same treatment for the study and will have to switch to a different class (i.e., previously treated with glatiramer acetate will switch to interferon beta preparaption, previously treated with interferon beta preparation will swtich to glatiramer acetate).

Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS, EDSS < or equal to 6, not pregnant or planning pregnancy and women of childbearing potential willing to use contraception throughout the study.

Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system, active macular edema, systemic bacterial, viral or fungal infections, patients without vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of screening, history of various cardiac conditions, presence of certain ECG abnormalities, resting heart rate < 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic disorders, pregnancy.

Patients may switch treatment before 3 months for safety reasons only, after 3 months for safety, efficacy, tolerability or convenience. Treatment switch during the study may be to any of study approved treatments irrespective of prior treatment.

Patients randomized to fingolimod will need to have 6 hours of observation for signs and symptoms of bradycardia following administration of the first dose. Extended observation or overnight observation may be necessary under certain circumstances. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI. Exploratory objectives include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported outcome measures.

Study Design

Study Type:
Interventional
Actual Enrollment :
881 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Actual Study Start Date :
Jun 8, 2012
Actual Primary Completion Date :
Jul 13, 2015
Actual Study Completion Date :
Jul 13, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fingolimod

Drug: Fingolimod

Active Comparator: Disease Modifying Therapy

2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)

Drug: Disease Modifying therapy

Outcome Measures

Primary Outcome Measures

  1. Participant Retention Rate Over 12 Months [at 12 months]

    Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)

Secondary Outcome Measures

  1. Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set [at 12 months]

    Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.

  2. Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase) [baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation]

    Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

  3. Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase) [baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation]

    Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

  4. Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized) [12 months, and Last assessment which is either at Month 12 or at early discontinuation]

    Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI

  5. Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score [Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months & Last assessment during randomized phase which is either at Month 12 or at early discontinuation]

    Summary statistics for Medication Satisfaction Questionnaire[Question: "Overall, how satisfied are you with your current medication?"] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. written informed consent must be obtained prior to any assessment being performed.

  2. Male and female patients aged 18-65 years inclusive.

  3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald criteria (Pollman et al, 2011) (Appendix 1).

  4. EDSS score of less than or equal to 6.

  5. Patients naive to treatment or who have been treated with no more than one class of DMT previously (interferon β preparation or glatiramer acetate), and who, per investigator judgment, may benefit from a change of treatment class.

  6. Patients who have been treated with DMF for less than 2 months total exposure and who have a normal lymphocyte count at screening.

  7. Women of childbearing potential must have a negative urine and serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and at baseline.

  8. Before entry women must be:

  • Post menopausal for at least 1 year, or

  • Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise incapable of pregnancy, or

  • Practicing a highly effective method of birth control if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study, or

  • Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) 4.2 Exclusion criteria

  1. Use of other investigational drugs within 30 days of screening.

  2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.

  3. Prior exposure to fingolimod or any other S1P receptor modulating compounds.

  4. History or presence of malignancy of any organ system (other than successfully treated basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.

  5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive MS (PPMS).

  6. Patients with a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.

  7. Patients who have been treated with:

• Natalizumab, mitoxantrone, cladribine, rituximab, alemtuzumab, ofatumumab, ocrelizumab at any time before randomization

• Immunoglobulins, or pulse of corticosteroids with more than 6 months cumulative exposure

• Immunosuppressive/chemotherapeutic medications (e.g., methotrexate, azathioprine, cyclophosphamide, cellcept, Cytoxan, IVIG) with more than 6 months of cumulative exposure and within 6 months prior to randomization

• Corticosteroids or adrenocorticotropic hormones in the past 30 days before randomization. Patients that require corticosteroids for a relapse during the screening period may be rescreened 30 days after the last dose.

  1. History of treatment with both classes of approved first line DMT (interferon β preparation and glatiramer acetate) or DMF exposure of 2 months or longer.

  2. Patients with uncontrolled diabetes mellitus (HbA1c > 7%).

  3. Diagnosis of macular edema during the screening phase. Patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at the screening visit.

  4. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.

  5. Patients without history of chickenpox or without vaccination against varicella-zoster virus at screening (patients may be vaccinated and rescreened one month or longer after vaccination).

  6. Patients who have received any live or live attenuated vaccines (including for varicella-zoster or measles) within 1 month prior to baseline.

  7. Patients with any medically unstable condition as assessed by the investigator.

  8. Patients with a history of the following cardiovascular conditions:

• Cardiac arrest.

• myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure (Appendix 3).

• Congestive heart failure.

• Hypertension that is not controlled with prescribed medications. These patients may be rescreened if blood pressure is stabilized with treatment.

• Cerebrovascular disease.

• History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker.

• Patients at higher risk of symptomatic bradycardia or heart block because of a coexisting medical condition or certain concomitant medications.

• Patients randomized to the fingolimod arm with prolonged QTc interval at screening (corrected QT interval > 450 ms in males and > 470 ms in females); for patients randomized to the fingolimod treatment arm before dosing (baseline) or during the 6-hour observation period; and those patients at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant therapy with QT prolonging drugs with a known risk of Torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin).

  • Patients receiving class Ia or Class III antiarrhythmic drugs (Appendix 6)

  • Patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart-rate slowing calcium channel blockers such as diltiazem, verapamil or digoxin). The possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction should be evaluated by the physician prescribing these drugs before initiating fingolimod treatment.

  • History of sick sinus syndrome or sinoatrial heart block.

  • Resting heart rate of < 45 bpm or symptomatic bradycardia

  • Recurrent syncope

  • Severe untreated sleep apnea

  1. Patients with severe pulmonary conditions (including severe respiratory disease, pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma).

  2. Patients with any of the following hepatic conditions:

• Chronic liver or biliary disease

  • Total bilirubin greater than upper limit of normal (ULN) at screening unless in the context of Gilbert's syndrome

  • Conjugated bilirubin greater than the ULN at screening

  • AST (SGOT), ALT (SGPT) greater than 3 times ULN at screening

  • Alkaline phosphatase (AP) greater than 1.5 times the ULN at screening

  1. Serum creatinine greater than 2.0 mg/dL (176.5 µmol/L) at screening.

  2. Patients with the following neurological/psychiatric disorders:

  • History of substance abuse (drug or alcohol) in the past five years as determined by the investigator

  • Progressive neurological disorder other than MS which may affect study participation as determined by the investigator

  • Any serious psychiatric condition that may interfere with the patient's ability to cooperate and comply with the study procedures as determined by the investigator

  1. Women who are pregnant or nursing (lactating) or planning to become pregnant.

  2. Any condition that in the opinion of the investigator, would compromise the well-being of the patient or the conduct of the study, or prevent the patient from meeting or performing study requirements.

  3. Pre-planned surgery or medical procedure that would interfere with the conduct of the study.

  4. Employee of the sponsor, investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Novartis Investigative Site Cullman Alabama United States 35058
2 Novartis Investigative Site Phoenix Arizona United States 85004
3 Novartis Investigative Site Sun City Arizona United States 85351
4 Novartis Investigative Site Tucson Arizona United States 85741
5 Novartis Investigative Site Sherwood Arkansas United States 72120
6 Novartis Investigative Site Fullerton California United States 92835
7 Novartis Investigative Site Oceanside California United States 92056
8 Novartis Investigative Site San Francisco California United States 94117
9 Novartis Investigative Site Walnut Creek California United States 94598
10 Novartis Investigative Site Basalt Colorado United States 81621
11 Novartis Investigative Site Boulder Colorado United States 80301
12 Novartis Investigative Site Denver Colorado United States 80209
13 Novartis Investigative Site Denver Colorado United States 80210
14 Novartis Investigative Site Fort Collins Colorado United States 80528
15 Novartis Investigative Site Fairfield Connecticut United States 06824
16 Novartis Investigative Site New London Connecticut United States 06320
17 Novartis Investigative Site Dover Delaware United States 19901
18 Novartis Investigative Site Atlantis Florida United States 33462-6608
19 Novartis Investigative Site Bradenton Florida United States 34205
20 Novartis Investigative Site Delray Beach Florida United States 33445
21 Novartis Investigative Site Hollywood Florida United States 33021
22 Novartis Investigative Site Jacksonville Florida United States 32216
23 Novartis Investigative Site North Palm Beach Florida United States 33408
24 Novartis Investigative Site Plantation Florida United States 33324
25 Novartis Investigative Site Pompano Beach Florida United States 33060
26 Novartis Investigative Site Port Charlotte Florida United States 33952
27 Novartis Investigative Site Port Orange Florida United States 32127
28 Novartis Investigative Site Saint Petersburg Florida United States 33713
29 Novartis Investigative Site Sarasota Florida United States 34233
30 Novartis Investigative Site Sarasota Florida United States 34243
31 Novartis Investigative Site Tallahassee Florida United States 32308
32 Novartis Investigative Site Tampa Florida United States 33609
33 Novartis Investigative Site West Palm Beach Florida United States 33407
34 Novartis Investigative Site Atlanta Georgia United States 30312
35 Novartis Investigative Site Columbus Georgia United States 31904
36 Novartis Investigative Site Decatur Georgia United States 30083
37 Novartis Investigative Site Suwanee Georgia United States 30024
38 Novartis Investigative Site Flossmoor Illinois United States 60422
39 Novartis Investigative Site Northbrook Illinois United States 60062
40 Novartis Investigative Site Anderson Indiana United States 46011
41 Novartis Investigative Site Indianapolis Indiana United States 46227
42 Novartis Investigative Site Indianapolis Indiana United States 46256
43 Novartis Investigative Site Des Moines Iowa United States 50314-2611
44 Novartis Investigative Site Overland Park Kansas United States
45 Novartis Investigative Site Wichita Kansas United States 67214
46 Novartis Investigative Site Hawesville Kentucky United States 42384
47 Novartis Investigative Site Lexington Kentucky United States 40504
48 Novartis Investigative Site Madisonville Kentucky United States 42431
49 Novartis Investigative Site Alexandria Louisiana United States 71301
50 Novartis Investigative Site Baton Rouge Louisiana United States 70809
51 Novartis Investigative Site New Orleans Louisiana United States 70115
52 Novartis Investigative Site Annapolis Maryland United States 21401
53 Novartis Investigative Site Fulton Maryland United States 20759
54 Novartis Investigative Site New Bedford Massachusetts United States 02740
55 Novartis Investigative Site North Dartmouth Massachusetts United States 02747
56 Novartis Investigative Site Springfield Massachusetts United States 01104
57 Novartis Investigative Site Watertown Massachusetts United States 02472
58 Novartis Investigative Site Worcester Massachusetts United States 01608
59 Novartis Investigative Site Kalamazoo Michigan United States 49007
60 Novartis Investigative Site Traverse City Michigan United States 49684-2340
61 Novartis Investigative Site Nixa Missouri United States 65714-7807
62 Novartis Investigative Site North Kansas City Missouri United States 64116
63 Novartis Investigative Site Saint Louis Missouri United States 63104
64 Novartis Investigative Site Las Vegas Nevada United States 89121
65 Novartis Investigative Site Las Vegas Nevada United States 89123
66 Novartis Investigative Site Las Vegas Nevada United States 89144
67 Novartis Investigative Site Flemington New Jersey United States 08822
68 Novartis Investigative Site Teaneck New Jersey United States 07666
69 Novartis Investigative Site Toms River New Jersey United States 08755
70 Novartis Investigative Site Albuquerque New Mexico United States 87108
71 Novartis Investigative Site Albany New York United States 12208
72 Novartis Investigative Site Amherst New York United States 14226
73 Novartis Investigative Site Bronx New York United States 10467-2490
74 Novartis Investigative Site Kingston New York United States 12401
75 Novartis Investigative Site Latham New York United States 12110
76 Novartis Investigative Site New York New York United States 10003
77 Novartis Investigative Site Patchogue New York United States 11772
78 Novartis Investigative Site Asheville North Carolina United States 28806
79 Novartis Investigative Site Charlotte North Carolina United States 28202
80 Novartis Investigative Site Charlotte North Carolina United States 28204
81 Novartis Investigative Site Greensboro North Carolina United States 27401
82 Novartis Investigative Site Greenville North Carolina United States 27834
83 Novartis Investigative Site Raleigh North Carolina United States 27607
84 Novartis Investigative Site Salisbury North Carolina United States 28144
85 Novartis Investigative Site Winston-Salem North Carolina United States 27103
86 Novartis Investigative Site Grand Forks North Dakota United States 58201
87 Novartis Investigative Site Akron Ohio United States 44320
88 Novartis Investigative Site Bellevue Ohio United States 44811
89 Novartis Investigative Site Canton Ohio United States 44718
90 Novartis Investigative Site Cincinnati Ohio United States 45219
91 Novartis Investigative Site Columbus Ohio United States 43221
92 Novartis Investigative Site Dayton Ohio United States 45408
93 Novartis Investigative Site Toledo Ohio United States 43623
94 Novartis Investigative Site Oklahoma City Oklahoma United States 73104
95 Novartis Investigative Site Oklahoma City Oklahoma United States 73112
96 Novartis Investigative Site Eugene Oregon United States 97401
97 Novartis Investigative Site Greensburg Pennsylvania United States 15601
98 Novartis Investigative Site Hershey Pennsylvania United States 17033-0850
99 Novartis Investigative Site Pittsburgh Pennsylvania United States 15212
100 Novartis Investigative Site Cranston Rhode Island United States 02920
101 Novartis Investigative Site Indian Land South Carolina United States 29707
102 Novartis Investigative Site Spartanburg South Carolina United States 29302
103 Novartis Investigative Site Spartanburg South Carolina United States 29307
104 Novartis Investigative Site Cordova Tennessee United States 38018
105 Novartis Investigative Site Knoxville Tennessee United States 37920
106 Novartis Investigative Site Nashville Tennessee United States 37205
107 Novartis Investigative Site Colleyville Texas United States 76034
108 Novartis Investigative Site Houston Texas United States 77074
109 Novartis Investigative Site Lubbock Texas United States 79410
110 Novartis Investigative Site North Richland Hills Texas United States 76180
111 Novartis Investigative Site Plano Texas United States 75075
112 Novartis Investigative Site Round Rock Texas United States 78681
113 Novartis Investigative Site San Antonio Texas United States 78229
114 Novartis Investigative Site Orem Utah United States 84058
115 Novartis Investigative Site Alexandria Virginia United States 22310
116 Novartis Investigative Site Norfolk Virginia United States 23507
117 Novartis Investigative Site Vienna Virginia United States 22182
118 Novartis Investigative Site Bothell Washington United States 98011
119 Novartis Investigative Site Seattle Washington United States 98101
120 Novartis Investigative Site Tacoma Washington United States 98405
121 Novartis Investigative Site Morgantown West Virginia United States 26506-9260
122 Novartis Investigative Site Neenah Wisconsin United States 54956
123 Novartis Investigative Site Guaynabo Puerto Rico 00968

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01623596
Other Study ID Numbers:
  • CFTY720DUS09
First Posted:
Jun 20, 2012
Last Update Posted:
Jan 5, 2021
Last Verified:
Mar 1, 2019

Study Results

Participant Flow

Recruitment Details 62 Fingolimod arm participants discontinued: 57 discontinued before treatment switch, and 5 discontinued after treatment switch 100 MS-DMT arm participants discontinued before treatment switch: 57 discontinued before treatment switch, and 43 discontinued after treatment switch
Pre-assignment Detail Patient disposition was summarized on the Randomized Set. Randomized Set (RS): consists of all participants who were assigned randomization numbers.
Arm/Group Title Fingolimod Disease Modifying Therapy
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Period Title: Overall Study
STARTED 436 439
On Randomized Treatment 352 125
On Switched Treatment 22 214
COMPLETED 374 339
NOT COMPLETED 62 100

Baseline Characteristics

Arm/Group Title Fingolimod Disease Modifying Therapy (MS_DMT) Total
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone) Total of all reporting groups
Overall Participants 436 439 875
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
41.5
(10.84)
41.9
(10.39)
41.7
(10.61)
Sex: Female, Male (Count of Participants)
Female
311
71.3%
329
74.9%
640
73.1%
Male
125
28.7%
110
25.1%
235
26.9%

Outcome Measures

1. Primary Outcome
Title Participant Retention Rate Over 12 Months
Description Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)
Time Frame at 12 months

Outcome Measure Data

Analysis Population Description
Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.
Arm/Group Title Fingolimod Disease Modifying Therapy (MS-DMT)
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 436 439
Number [participants]
352
80.7%
125
28.5%
2. Secondary Outcome
Title Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set
Description Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.
Time Frame at 12 months

Outcome Measure Data

Analysis Population Description
Randomized set (RS): consists of all patients who were assigned randomization numbers. The patients in this set were called randomized patients. This set was used to summarize patient disposition, demographic and baseline characteristics, and protocol deviation information. Patients were grouped according to randomized treatment.
Arm/Group Title Fingolimod Disease Modifying Therapy (MS-DMT)
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 436 439
Occurrence of relapse (Primary reason)
5
1.1%
14
3.2%
Disease activity present in MRI (Primary reason)
0
0%
6
1.4%
Injection site reaction (Primary reason)
0
0%
61
13.9%
Flu-like symptoms (Primary reason)
0
0%
34
7.7%
Lipoatrophy (Primary reason)
0
0%
1
0.2%
Depression (Primary reason)
1
0.2%
4
0.9%
Hepatic side effects (Primary reason)
7
1.6%
3
0.7%
Spasticity (Primary reason)
0
0%
1
0.2%
Infection (Primary reason)
0
0%
0
0%
Macular edema (Primary reason)
1
0.2%
0
0%
Bradycardia (Primary reason)
0
0%
0
0%
Needle phobia (Primary reason)
0
0%
13
3%
Inconvenient administration (Primary reason)
0
0%
33
7.5%
Frequency of injections (Primary reason)
0
0%
29
6.6%
Neutralizing antibodies present (Primary reason)
0
0%
0
0%
Other (Primary reason)
13
3%
58
13.2%
Occurrence of relapse (Secondary reason)
0
0%
3
0.7%
Disease activity present in MRI (Secondary reason)
2
0.5%
5
1.1%
Injection site reaction (Secondary reason)
0
0%
40
9.1%
Flu-like symptoms (Secondary reason)
1
0.2%
16
3.6%
Lipoatrophy (Secondary reason)
0
0%
1
0.2%
Depression (Secondary reason)
0
0%
6
1.4%
Hepatic side effects (Secondary reason)
5
1.1%
0
0%
Spasticity (Secondary reason)
1
0.2%
2
0.5%
Infection (Secondary reason)
0
0%
0
0%
Macular edema (Secondary reason)
1
0.2%
0
0%
Bradycardia (Secondary reason)
0
0%
0
0%
Needle phobia (Secondary reason)
0
0%
18
4.1%
Inconvenient administration (Secondary reason)
0
0%
55
12.5%
Frequency of injections (Secondary reason)
0
0%
45
10.3%
Neutralizing antibodies present (Secondary reason)
0
0%
0
0%
Other (Secondary reason)
17
3.9%
65
14.8%
3. Secondary Outcome
Title Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)
Description Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
Time Frame baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation

Outcome Measure Data

Analysis Population Description
Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.
Arm/Group Title Fingolimod Disease Modifying Therapy (MS-DMT)
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 433 428
Baseline (n=76,70)
52.00
(12.12)
51.60
(13.40)
Change at 6 months (n=70,64)
2.20
(8.09)
0.20
(10.13)
Change at 12 months (n=58, 18)
3.20
(7.09)
1.40
(8.33)
Change at Last assessment (n=73, 65)
3.30
(7.77)
0.40
(9.47)
4. Secondary Outcome
Title Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)
Description Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.
Time Frame baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation

Outcome Measure Data

Analysis Population Description
Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.
Arm/Group Title Fingolimod Disease Modifying Therapy (MS-DMT)
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 433 428
Baseline (n=355,348)
48.90
(18.26)
48.50
(20.19)
Change at 6 months (n=339,322)
-0.50
(14.04)
0.70
(13.16)
Change at 12 months (n=282,105)
0.70
(16.02)
0.40
(14.90)
Change at Last assessment (n=342, 324)
0.80
(16.27)
0.70
(13.95)
5. Secondary Outcome
Title Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)
Description Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI
Time Frame 12 months, and Last assessment which is either at Month 12 or at early discontinuation

Outcome Measure Data

Analysis Population Description
Full analysis set includes all the patients who received at least one dose of study medication and had information on the primary end point.
Arm/Group Title Fingolimod Disease Modifying Therapy
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 433 428
Percent change at 12 months (n=323, 111)
-0.396
(0.7825)
-0.555
(0.7181)
Percent change at Last assessment (n=370, 246)
-0.385
(0.7690)
-0.420
(0.6423)
6. Secondary Outcome
Title Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score
Description Summary statistics for Medication Satisfaction Questionnaire[Question: "Overall, how satisfied are you with your current medication?"] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT
Time Frame Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months & Last assessment during randomized phase which is either at Month 12 or at early discontinuation

Outcome Measure Data

Analysis Population Description
Full analysis set (FAS) includes all the patients who received at least one dose of study medication and had information on the primary end point.
Arm/Group Title Fingolimod Disease Modifying Therapy (DS-DMT)
Arm/Group Description fingolimod 0.5 mg once a day 2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Measure Participants 433 428
Baseline, Extremely dissatisfied
10
(4.7) 2.3%
16
(7.2) 3.6%
Baseline, Very dissatisfied
22
(10.3) 5%
13
(5.8) 3%
Baseline, Somewhat dissatisfied
29
(13.6) 6.7%
39
(17.5) 8.9%
Baseline, Neither dissatisfied nor satisfied
62
(29.0) 14.2%
61
(27.4) 13.9%
Baseline, Somewhat satisfied
35
(16.4) 8%
46
(20.6) 10.5%
Baseline, Very satisfied
42
(19.6) 9.6%
31
(13.9) 7.1%
Baseline, Extremely satisfied
14
(6.5) 3.2%
17
(7.6) 3.9%
Baseline, Missing
219
(0) 50.2%
205
(0) 46.7%
1 month, Extremely dissatisfied
8
(1.9) 1.8%
29
(6.9) 6.6%
1 month, Very dissatisfied
14
(3.3) 3.2%
37
(8.9) 8.4%
1 month, Somewhat dissatisfied
8
(1.9) 1.8%
52
(12.4) 11.8%
1 month, Neither dissatisfied nor satisfied
32
(7.5) 7.3%
74
(17.7) 16.9%
1 month, Somewhat satisfied
52
(12.1) 11.9%
89
(21.3) 20.3%
1 month, Very satisfied
161
(37.5) 36.9%
97
(23.2) 22.1%
1 month, Extremely satisfied
154
(35.9) 35.3%
40
(9.6) 9.1%
1 month, Missing
4
(0) 0.9%
10
(0) 2.3%
3 months, Extremely dissatisfied
5
(1.2) 1.1%
19
(5.5) 4.3%
3 months, Very dissatisfied
11
(2.7) 2.5%
38
(11.0) 8.7%
3 months, Somewhat dissatisfied
11
(2.7) 2.5%
42
(12.1) 9.6%
3 months, Neither dissatisfied nor satisfied
46
(11.1) 10.6%
53
(15.3) 12.1%
3 months, Somewhat satisfied
43
(10.4) 9.9%
73
(21.1) 16.6%
3 months, Very satisfied
153
(37.0) 35.1%
91
(26.3) 20.7%
3 months, Extremely satisfied
144
(34.9) 33%
30
(8.7) 6.8%
3 months, Missing
20
(0) 4.6%
82
(0) 18.7%
6 months, Extremely dissatisfied
8
(2.0) 1.8%
9
(4.6) 2.1%
6 months, Very dissatisfied
15
(3.8) 3.4%
11
(5.6) 2.5%
6 months, Somewhat dissatisfied
11
(2.8) 2.5%
13
(6.6) 3%
6 months, Neither dissatisfied nor satisfied
25
(6.3) 5.7%
24
(12.2) 5.5%
6 months, Somewhat satisfied
57
(14.4) 13.1%
46
(23.5) 10.5%
6 months, Very satisfied
130
(32.7) 29.8%
67
(34.2) 15.3%
6 months, Extremely satisfied
151
(38.0) 34.6%
26
(13.3) 5.9%
6 months, Missing
36
(0) 8.3%
232
(0) 52.8%
9 months, Extremely dissatisfied
7
(1.9) 1.6%
4
(2.6) 0.9%
9 months, Very dissatisfied
8
(2.2) 1.8%
6
(3.9) 1.4%
9 months, Somewhat dissatisfied
12
(3.2) 2.8%
12
(7.8) 2.7%
9 months, Neither dissatisfied nor satisfied
21
(5.7) 4.8%
15
(9.8) 3.4%
9 months, Somewhat satisfied
42
(11.4) 9.6%
29
(19.0) 6.6%
9 months, Very satisfied
135
(36.5) 31%
58
(37.9) 13.2%
9 months, Extremely satisfied
145
(39.2) 33.3%
29
(19.0) 6.6%
9 months, Missing
63
(0) 14.4%
275
(0) 62.6%
12 months, Extremely dissatisfied
7
(2.0) 1.6%
3
(2.4) 0.7%
12 months, Very dissatisfied
7
(2.0) 1.6%
4
(3.1) 0.9%
12 months, Somewhat dissatisfied
11
(3.1) 2.5%
4
(3.1) 0.9%
12 months, Neither dissatisfied nor satisfied
27
(7.7) 6.2%
8
(6.3) 1.8%
12 months, Somewhat satisfied
34
(9.7) 7.8%
22
(7.3) 5%
12 months, Very satisfied
115
(32.8) 26.4%
60
(47.2) 13.7%
12 months, Extremely satisfied
150
(42.7) 34.4%
26
(20.5) 5.9%
12 months, Missing
82
(0) 18.8%
301
(0) 68.6%
Last assessment, Extremely dissatisfied
14
(3.3) 3.2%
46
(10.9) 10.5%
Last assessment, Very dissatisfied
15
(3.5) 3.4%
61
(14.5) 13.9%
Last assessment, Somewhat dissatisfied
23
(5.3) 5.3%
57
(13.5) 13%
Last assessment,Neither dissatisfied nor satisfied
45
(10.5) 10.3%
58
(13.7) 13.2%
Last assessment, Somewhat satisfied
43
(10.0) 9.9%
69
(16.4) 15.7%
Last assessment, Very satisfied
128
(29.8) 29.4%
94
(22.3) 21.4%
Last assessment, Extremely satisfied
162
(37.7) 37.2%
37
(8.8) 8.4%
Last assessment, Missing
3
(0) 0.7%
6
(0) 1.4%

Adverse Events

Time Frame
Adverse Event Reporting Description
Arm/Group Title Fingolimod MS DMT
Arm/Group Description Fingolimod MS DMT
All Cause Mortality
Fingolimod MS DMT
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total / (NaN) / (NaN)
Serious Adverse Events
Fingolimod MS DMT
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 29/433 (6.7%) 15/428 (3.5%)
Blood and lymphatic system disorders
Leukocytosis 0/433 (0%) 1/428 (0.2%)
Cardiac disorders
Acute myocardial infarction 1/433 (0.2%) 0/428 (0%)
Atrioventricular block second degree 1/433 (0.2%) 0/428 (0%)
Bradycardia 1/433 (0.2%) 0/428 (0%)
Cardio-respiratory arrest 0/433 (0%) 1/428 (0.2%)
Myocardial infarction 1/433 (0.2%) 0/428 (0%)
Eye disorders
Macular oedema 1/433 (0.2%) 0/428 (0%)
Visual impairment 1/433 (0.2%) 0/428 (0%)
Gastrointestinal disorders
Abdominal pain 0/433 (0%) 1/428 (0.2%)
Abdominal pain lower 1/433 (0.2%) 0/428 (0%)
Duodenal ulcer perforation 1/433 (0.2%) 0/428 (0%)
Gastric ulcer 1/433 (0.2%) 0/428 (0%)
Gastritis 1/433 (0.2%) 0/428 (0%)
Gastrooesophageal reflux disease 0/433 (0%) 1/428 (0.2%)
Jejunal ulcer 1/433 (0.2%) 0/428 (0%)
Pneumoperitoneum 1/433 (0.2%) 0/428 (0%)
Umbilical hernia 0/433 (0%) 1/428 (0.2%)
General disorders
Asthenia 1/433 (0.2%) 0/428 (0%)
Localised oedema 1/433 (0.2%) 0/428 (0%)
Systemic inflammatory response syndrome 1/433 (0.2%) 0/428 (0%)
Hepatobiliary disorders
Biliary colic 1/433 (0.2%) 0/428 (0%)
Cholecystitis acute 0/433 (0%) 1/428 (0.2%)
Cholelithiasis 0/433 (0%) 1/428 (0.2%)
Infections and infestations
Bacteraemia 1/433 (0.2%) 0/428 (0%)
Campylobacter gastroenteritis 1/433 (0.2%) 0/428 (0%)
Cellulitis 1/433 (0.2%) 0/428 (0%)
Pneumonia 2/433 (0.5%) 0/428 (0%)
Pneumonia influenzal 1/433 (0.2%) 0/428 (0%)
Pyelonephritis acute 1/433 (0.2%) 0/428 (0%)
Tooth abscess 1/433 (0.2%) 0/428 (0%)
Viral infection 1/433 (0.2%) 0/428 (0%)
Injury, poisoning and procedural complications
Gastrointestinal stoma complication 1/433 (0.2%) 0/428 (0%)
Intentional overdose 0/433 (0%) 1/428 (0.2%)
Pubis fracture 1/433 (0.2%) 0/428 (0%)
Seroma 1/433 (0.2%) 0/428 (0%)
Spinal fracture 1/433 (0.2%) 0/428 (0%)
Suture related complication 1/433 (0.2%) 0/428 (0%)
Metabolism and nutrition disorders
Dehydration 2/433 (0.5%) 0/428 (0%)
Musculoskeletal and connective tissue disorders
Muscular weakness 1/433 (0.2%) 0/428 (0%)
Myopathy 1/433 (0.2%) 0/428 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma 1/433 (0.2%) 0/428 (0%)
Nervous system disorders
Dizziness 0/433 (0%) 1/428 (0.2%)
Headache 1/433 (0.2%) 0/428 (0%)
Hemiparesis 0/433 (0%) 1/428 (0.2%)
Hypoaesthesia 0/433 (0%) 1/428 (0.2%)
Mental impairment 0/433 (0%) 1/428 (0.2%)
Multiple sclerosis relapse 5/433 (1.2%) 5/428 (1.2%)
Optic neuritis 1/433 (0.2%) 0/428 (0%)
Paraesthesia 1/433 (0.2%) 0/428 (0%)
Sciatica 0/433 (0%) 1/428 (0.2%)
Syncope 1/433 (0.2%) 0/428 (0%)
Psychiatric disorders
Agoraphobia 0/433 (0%) 1/428 (0.2%)
Anxiety 1/433 (0.2%) 2/428 (0.5%)
Depression 1/433 (0.2%) 0/428 (0%)
Homicidal ideation 1/433 (0.2%) 0/428 (0%)
Major depression 1/433 (0.2%) 0/428 (0%)
Panic disorder 0/433 (0%) 1/428 (0.2%)
Personality disorder 0/433 (0%) 1/428 (0.2%)
Suicidal ideation 2/433 (0.5%) 0/428 (0%)
Renal and urinary disorders
Calculus urinary 1/433 (0.2%) 0/428 (0%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea 0/433 (0%) 1/428 (0.2%)
Pleurisy 1/433 (0.2%) 0/428 (0%)
Pneumothorax 1/433 (0.2%) 0/428 (0%)
Surgical and medical procedures
Abortion induced 1/433 (0.2%) 1/428 (0.2%)
Vascular disorders
Haematoma 1/433 (0.2%) 0/428 (0%)
Other (Not Including Serious) Adverse Events
Fingolimod MS DMT
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 282/433 (65.1%) 291/428 (68%)
Blood and lymphatic system disorders
Lymphopenia 30/433 (6.9%) 1/428 (0.2%)
Gastrointestinal disorders
Diarrhoea 26/433 (6%) 5/428 (1.2%)
Nausea 29/433 (6.7%) 22/428 (5.1%)
General disorders
Fatigue 49/433 (11.3%) 33/428 (7.7%)
Influenza like illness 12/433 (2.8%) 64/428 (15%)
Injection site erythema 0/433 (0%) 42/428 (9.8%)
Injection site pain 0/433 (0%) 62/428 (14.5%)
Injection site pruritus 0/433 (0%) 30/428 (7%)
Injection site reaction 0/433 (0%) 50/428 (11.7%)
Infections and infestations
Nasopharyngitis 41/433 (9.5%) 22/428 (5.1%)
Sinusitis 28/433 (6.5%) 21/428 (4.9%)
Upper respiratory tract infection 27/433 (6.2%) 21/428 (4.9%)
Urinary tract infection 23/433 (5.3%) 16/428 (3.7%)
Investigations
Lymphocyte count decreased 23/433 (5.3%) 0/428 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia 30/433 (6.9%) 17/428 (4%)
Back pain 29/433 (6.7%) 14/428 (3.3%)
Pain in extremity 18/433 (4.2%) 23/428 (5.4%)
Nervous system disorders
Dizziness 31/433 (7.2%) 12/428 (2.8%)
Headache 40/433 (9.2%) 41/428 (9.6%)
Hypoaesthesia 23/433 (5.3%) 15/428 (3.5%)
Migraine 22/433 (5.1%) 14/428 (3.3%)
Paraesthesia 22/433 (5.1%) 17/428 (4%)
Psychiatric disorders
Anxiety 13/433 (3%) 24/428 (5.6%)
Depression 26/433 (6%) 29/428 (6.8%)
Respiratory, thoracic and mediastinal disorders
Cough 25/433 (5.8%) 15/428 (3.5%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial

Results Point of Contact

Name/Title Study Director
Organization Novartis Pharmaceuticals
Phone (862) 778-8300
Email
Responsible Party:
Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01623596
Other Study ID Numbers:
  • CFTY720DUS09
First Posted:
Jun 20, 2012
Last Update Posted:
Jan 5, 2021
Last Verified:
Mar 1, 2019